1
|
Barabási B, Barna L, Santa-Maria AR, Harazin A, Molnár R, Kincses A, Vigh JP, Dukay B, Sántha M, Tóth ME, Walter FR, Deli MA, Hoyk Z. Role of interleukin-6 and interleukin-10 in morphological and functional changes of the blood-brain barrier in hypertriglyceridemia. Fluids Barriers CNS 2023; 20:15. [PMID: 36882782 PMCID: PMC9990353 DOI: 10.1186/s12987-023-00418-3] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2022] [Accepted: 02/24/2023] [Indexed: 03/09/2023] Open
Abstract
BACKGROUND Hypertriglyceridemia is closely linked to atherosclerosis related inflammatory processes and blood-brain barrier (BBB) dysfunction. Using apolipoprotein B-100 (APOB-100) transgenic mice, an animal model of chronic hypertriglyceridemia, we analyzed BBB function and morphology in vitro and ex vivo. Our objective was to determine which BBB characteristics are produced mainly by interleukin (IL)-6, an atherosclerosis promoting cytokine, and whether these actions can be antagonized by IL-10, an anti-inflammatory cytokine. METHODS Brain endothelial and glial cell cultures and brain microvessels were isolated from wild type (WT) and APOB-100 transgenic mice and were treated with IL-6, IL-10 and their combination. First, IL-6 and IL-10 production was measured in WT and APOB-100 microvessels using qPCR. Then functional parameters of endothelial cell cultures were analyzed and immunocytochemistry for key BBB proteins was performed. RESULTS IL-6 mRNA levels were higher in brain microvessels than in brain parenchyma of APOB-100 transgenic mice. Transendothelial electric resistance and P-glycoprotein activity were lower, and paracellular permeability was higher in cultured APOB-100 brain endothelial cells. These features were sensitive to both IL-6 and IL-10 treatments. A decreased P-glycoprotein immunostaining was measured in transgenic endothelial cells under control conditions and in WT cells after treating them with IL-6. This effect was antagonized by IL-10. Changes in immunostaining for tight junction proteins were observed after IL-6 exposure, which were in part antagonized by IL-10. In glial cell cultures an increase in aquaporin-4 immunolabeling in the transgenic group and an increase in microglia cell density in WT glia cultures was detected after IL-6 treatment, which was antagonized by IL-10. In isolated brain microvessels a decrease in P-glycoprotein immunolabeled area fraction was measured in APOB-100 microvessels under control conditions and in WT microvessels after every cytokine treatment. ZO-1 immunolabeling showed characteristics similar to that of P-glycoprotein. No change was seen in claudin-5 and occludin immunoreactive area fractions in microvessels. A decrease in aquaporin-4 immunoreactivity was measured in WT microvessels treated by IL-6, which was antagonized by IL-10. CONCLUSION IL-6 produced in microvessels contributes to BBB impairment observed in the APOB-100 mice. We showed that IL-10 partly antagonizes the effects of IL-6 at the BBB.
Collapse
Affiliation(s)
- Beáta Barabási
- Institute of Biophysics, Biological Research Centre, Temesvári Krt. 62, Szeged, 6726, Hungary.,Doctoral School of Theoretical Medicine, University of Szeged, Tisza L. Krt. 109, Szeged, 6725, Hungary
| | - Lilla Barna
- Institute of Biophysics, Biological Research Centre, Temesvári Krt. 62, Szeged, 6726, Hungary
| | - Ana Raquel Santa-Maria
- Institute of Biophysics, Biological Research Centre, Temesvári Krt. 62, Szeged, 6726, Hungary.,Wyss Institute for Biologically Inspired Engineering at Harvard University, 3 Blackfan Circle, Boston, MA, 02115, USA
| | - András Harazin
- Institute of Biophysics, Biological Research Centre, Temesvári Krt. 62, Szeged, 6726, Hungary
| | - Réka Molnár
- Institute of Biophysics, Biological Research Centre, Temesvári Krt. 62, Szeged, 6726, Hungary
| | - András Kincses
- Institute of Biophysics, Biological Research Centre, Temesvári Krt. 62, Szeged, 6726, Hungary
| | - Judit P Vigh
- Institute of Biophysics, Biological Research Centre, Temesvári Krt. 62, Szeged, 6726, Hungary
| | - Brigitta Dukay
- Institute of Biochemistry, Biological Research Centre, Temesvári Krt. 62, Szeged, 6726, Hungary
| | - Miklós Sántha
- Institute of Biochemistry, Biological Research Centre, Temesvári Krt. 62, Szeged, 6726, Hungary
| | - Melinda E Tóth
- Institute of Biochemistry, Biological Research Centre, Temesvári Krt. 62, Szeged, 6726, Hungary
| | - Fruzsina R Walter
- Institute of Biophysics, Biological Research Centre, Temesvári Krt. 62, Szeged, 6726, Hungary.
| | - Mária A Deli
- Institute of Biophysics, Biological Research Centre, Temesvári Krt. 62, Szeged, 6726, Hungary.
| | - Zsófia Hoyk
- Institute of Biophysics, Biological Research Centre, Temesvári Krt. 62, Szeged, 6726, Hungary.
| |
Collapse
|
2
|
Campelj DG, Timpani CA, Cree T, Petersen AC, Hayes A, Goodman CA, Rybalka E. Metronomic 5-Fluorouracil Delivery Primes Skeletal Muscle for Myopathy but Does Not Cause Cachexia. Pharmaceuticals (Basel) 2021; 14:478. [PMID: 34067869 DOI: 10.3390/ph14050478] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2021] [Revised: 05/10/2021] [Accepted: 05/12/2021] [Indexed: 12/22/2022] Open
Abstract
Skeletal myopathy encompasses both atrophy and dysfunction and is a prominent event in cancer and chemotherapy-induced cachexia. Here, we investigate the effects of a chemotherapeutic agent, 5-fluorouracil (5FU), on skeletal muscle mass and function, and whether small-molecule therapeutic candidate, BGP-15, could be protective against the chemotoxic challenge exerted by 5FU. Additionally, we explore the molecular signature of 5FU treatment. Male Balb/c mice received metronomic tri-weekly intraperitoneal delivery of 5FU (23 mg/kg), with and without BGP-15 (15 mg/kg), 6 times in total over a 15 day treatment period. We demonstrated that neither 5FU, nor 5FU combined with BGP-15, affected body composition indices, skeletal muscle mass or function. Adjuvant BGP-15 treatment did, however, prevent the 5FU-induced phosphorylation of p38 MAPK and p65 NF-B subunit, signalling pathways involved in cell stress and inflammatory signalling, respectively. This as associated with mitoprotection. 5FU reduced the expression of the key cytoskeletal proteins, desmin and dystrophin, which was not prevented by BGP-15. Combined, these data show that metronomic delivery of 5FU does not elicit physiological consequences to skeletal muscle mass and function but is implicit in priming skeletal muscle with a molecular signature for myopathy. BGP-15 has modest protective efficacy against the molecular changes induced by 5FU.
Collapse
|